JF
NKTR icon

Jump Financial’s Nektar Therapeutics NKTR Stock Holding History

Jump Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.57M Buy
77,402
+24,190
+45% +$1.38M 0.07% 324
2025
Q4 		$2.25M Buy
+53,212
New +$2.98M 0.03% 630
2023
Q2 		– Sell
-1,320
Closed -$13.9K – 2042
2023
Q1 		$13.9K Buy
+1,320
New +$39.9K ﹤0.01% 1510
2022
Q4 		– Sell
-9,293
Closed -$446K – 1882
2022
Q3 		$446K Sell
9,293
-2,278
-20% -$136K 0.02% 943
2022
Q2 		$659K Buy
11,571
+9,328
+416% +$589K 0.03% 732
2022
Q1 		$181K Buy
+2,243
New +$332K 0.01% 1326
2021
Q2 		– Sell
-1,567
Closed -$470K – 1298
2021
Q1 		$470K Buy
+1,567
New +$488K 0.04% 421

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jump Financial's NKTR Position: Q1 2026 in Review

Jump Financial increased its Nektar Therapeutics (NKTR) stake by 45% in Q1 2026, buying an estimated $1.38M and bringing the position to 77,402 shares worth $5.57M. The position accounts for 0.07% of the portfolio, ranked #324.

Jump Financial first reported a position in NKTR in Q1 2021 and has held it in 7 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Jump Financial held 77,402 shares of Nektar Therapeutics worth $5.57M as of Q1 2026.
  • Jump Financial bought 24,190 Nektar Therapeutics shares in Q1 2026, an estimated $1.38M.
  • Nektar Therapeutics made up 0.07% of Jump Financial's portfolio in Q1 2026, its #324 holding.
  • Jump Financial first reported a position in Nektar Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.